| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
United Therapeutics (NASDAQ:UTHR) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $318.0, along with a high estimate of $400.00 and a low estimate of $240.00. This upward trend is apparent, with the current average reflecting a 6.18% increase from the previous average price target of $299.50.
The perception of United Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tiago Fauth | Wells Fargo | Raises | Overweight | $350.00 | $325.00 |
| Jessica Fye | JP Morgan | Raises | Overweight | $300.00 | $280.00 |
| Chris Shibutani | Goldman Sachs | Raises | Neutral | $240.00 | $218.00 |
| Hartaj Singh | Oppenheimer | Raises | Outperform | $400.00 | $375.00 |
| Andrew Fein | HC Wainwright & Co. | Maintains | Buy | $300.00 | - |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of United Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on United Therapeutics analyst ratings.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: United Therapeutics's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 33.7%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: United Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 45.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): United Therapeutics's ROE excels beyond industry benchmarks, reaching 5.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): United Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 4.49%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: United Therapeutics's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: UTHR
